Tarsus Pharmaceuticals Competitors

Tarsus Pharmaceuticals (NASDAQ:TARS) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Tarsus Pharmaceuticals and Sorrento Therapeutics, as provided by MarketBeat.

Tarsus Pharmaceuticals currently has a consensus price target of $37.25, suggesting a potential upside of 27.13%. Sorrento Therapeutics has a consensus price target of $28.75, suggesting a potential upside of 316.67%. Given Sorrento Therapeutics' higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Tarsus Pharmaceuticals.

Profitability

This table compares Tarsus Pharmaceuticals and Sorrento Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Tarsus Pharmaceuticals and Sorrento Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Tarsus Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics.

Insider and Institutional Ownership

27.4% of Sorrento Therapeutics shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats Sorrento Therapeutics on 5 of the 9 factors compared between the two stocks.

bluebird bio (NASDAQ:BLUE) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for bluebird bio and Tarsus Pharmaceuticals, as provided by MarketBeat.com.

bluebird bio presently has a consensus price target of $61.40, indicating a potential upside of 121.34%. Tarsus Pharmaceuticals has a consensus price target of $37.25, indicating a potential upside of 27.13%. Given bluebird bio's higher probable upside, equities analysts plainly believe bluebird bio is more favorable than Tarsus Pharmaceuticals.

Earnings and Valuation

This table compares bluebird bio and Tarsus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Tarsus Pharmaceuticals has lower revenue, but higher earnings than bluebird bio.

Profitability

This table compares bluebird bio and Tarsus Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

94.3% of bluebird bio shares are held by institutional investors. 3.6% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rubius Therapeutics (NASDAQ:RUBY) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Rubius Therapeutics and Tarsus Pharmaceuticals, as reported by MarketBeat.

Rubius Therapeutics currently has a consensus target price of $23.3333, indicating a potential downside of 3.10%. Tarsus Pharmaceuticals has a consensus target price of $37.25, indicating a potential upside of 27.13%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Rubius Therapeutics.

Insider & Institutional Ownership

93.7% of Rubius Therapeutics shares are held by institutional investors. 58.4% of Rubius Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Rubius Therapeutics and Tarsus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Profitability

This table compares Rubius Therapeutics and Tarsus Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Tarsus Pharmaceuticals beats Rubius Therapeutics on 6 of the 8 factors compared between the two stocks.

Tarsus Pharmaceuticals (NASDAQ:TARS) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Profitability

This table compares Tarsus Pharmaceuticals and NantKwest's net margins, return on equity and return on assets.

Insider and Institutional Ownership

9.4% of NantKwest shares are owned by institutional investors. 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Tarsus Pharmaceuticals and NantKwest, as reported by MarketBeat.com.

Tarsus Pharmaceuticals currently has a consensus target price of $37.25, suggesting a potential upside of 27.13%. NantKwest has a consensus target price of $18.00, suggesting a potential upside of 11.87%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than NantKwest.

Earnings and Valuation

This table compares Tarsus Pharmaceuticals and NantKwest's gross revenue, earnings per share (EPS) and valuation.

Tarsus Pharmaceuticals has higher earnings, but lower revenue than NantKwest.

Summary

Tarsus Pharmaceuticals beats NantKwest on 7 of the 10 factors compared between the two stocks.

Tarsus Pharmaceuticals (NASDAQ:TARS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Tarsus Pharmaceuticals and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Tarsus Pharmaceuticals and BioCryst Pharmaceuticals' gross revenue, earnings per share and valuation.

Tarsus Pharmaceuticals has higher earnings, but lower revenue than BioCryst Pharmaceuticals.

Analyst Ratings

This is a summary of recent ratings and price targets for Tarsus Pharmaceuticals and BioCryst Pharmaceuticals, as provided by MarketBeat.com.

Tarsus Pharmaceuticals presently has a consensus target price of $37.25, suggesting a potential upside of 27.13%. BioCryst Pharmaceuticals has a consensus target price of $12.3333, suggesting a potential upside of 29.14%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Tarsus Pharmaceuticals.

Tarsus Pharmaceuticals (NASDAQ:TARS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Institutional and Insider Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Tarsus Pharmaceuticals and Sangamo Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Tarsus Pharmaceuticals and Sangamo Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Tarsus Pharmaceuticals has higher earnings, but lower revenue than Sangamo Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Tarsus Pharmaceuticals and Sangamo Therapeutics, as provided by MarketBeat.

Tarsus Pharmaceuticals presently has a consensus target price of $37.25, suggesting a potential upside of 27.13%. Sangamo Therapeutics has a consensus target price of $20.20, suggesting a potential upside of 82.15%. Given Sangamo Therapeutics' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Tarsus Pharmaceuticals.

Summary

Tarsus Pharmaceuticals beats Sangamo Therapeutics on 5 of the 9 factors compared between the two stocks.